Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
- 9 January 2001
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 56 (1) , 94-96
- https://doi.org/10.1212/wnl.56.1.94
Abstract
The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.Keywords
This publication has 8 references indexed in Scilit:
- Efficacy of Mycophenolate Mofetil in Patients Failing 6-Mercaptopurine or Azathioprine Therapy for Crohnʼs DiseaseInflammatory Bowel Diseases, 2000
- Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trialLupus, 1999
- Treatment of immune-mediated inflammatory neuropathiesCurrent Opinion in Neurology, 1999
- Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejectionTransplantation Proceedings, 1997
- IDIOPATHIC INFLAMMATORY MYOPATHIESNeurologic Clinics, 1997
- Myasthenia gravis: Immunological mechanisms and immunotherapyAnnals of Neurology, 1995
- Mechanisms of Action of Mycophenolic AcidAnnals of the New York Academy of Sciences, 1993
- Functional Activities of Autoantibodies to Acetylcholine Receptors and the Clinical Severity of Myasthenia GravisNew England Journal of Medicine, 1982